Only Buyers in this Pharma Stock Under Rs 35: Locked in Upper Circuit from 4th Straight Trading Session

On Wednesday, shares of Sudarshan Pharma Industries Ltd hit a 5 per cent Upper Circuit to Rs 30.06 per share from its previous closing of Rs 28.62 per share. The stock’s 52-week high is Rs 53.50 per share while its 52-week low is Rs 24.69 per share. The shares of the company saw a Spurt in Volume by more than 1.01 times on the BSE.

Sudarshan Pharma Industries Ltd., incorporated in 2008, is a Mumbai-based company specialising in the manufacturing of Active Pharmaceutical Ingredients (APIs) and pharmaceutical items, alongside trading in chemicals and solvents. They offer a diverse portfolio, from bulk chemicals and intermediates to finished formulations, with numerous products registered under their "R" trademark, including popular brands like Love Birds and Metfocal. The company operates both in India and international markets, including exports to countries in Southeast Asia, the Middle East, and North Africa.

According to the Quarterly Results, the net sales increased by 46.4 per cent to Rs 145.26 crore in Q1FY26 compared to Q1FY25. The company reported a turnaround net profit of Rs 3.96 crore compared to a net loss of Rs 1.21 crore in Q1FY25, an increase of 427.3 per cent YoY. In its annual results, the net sales increased by 9 per cent to Rs 505 crore and net profit increased by 45 per cent to Rs 16 crore in FY25 compared to FY24. The company has a market cap of Rs 770 crore and has delivered a good profit growth of 70 per cent CAGR over the last 5 years.

Sudarshan Pharma Industries Limited (SPIL) has successfully secured approval for a major modification to its greenfield projects under the Production Linked Incentive (PLI) Scheme, including changing the location from MIDC, Maharashtra to GIDC, Gujarat due to local resistance, and extending the commercial operation deadline for both its Vitamin B6 and Vitamin B1 projects to December 31, 2027, from the previous extended date of March 31, 2025. This approval comes alongside SPIL's strategic acquisition of Srujan Lifesciences Private Limited's fully operational manufacturing facility in Telangana for Rs 25.50 crore, which is intended to immediately boost the company's production capacity for high-value Active Pharmaceutical Ingredients (APIs) and specialty chemicals, accelerating its time-to-market for new products.

In June 2025, FIIs bought 24,84,000 shares and increased their stake by 19.49 per cent compared to March 2025. Additionally, the Government of India took a fresh entry and bought 1,28,000 shares or 0.05 per cent stake in the company. The stock is up by 21.75 per cent from its 52-week low of Rs 24.69 per share and has given multibagger returns of over 260 per cent in 2 years.

Disclaimer: The article is for informational purposes only and not investment advice.